Retatrutide: Eli Lilly’s “Triple Agonist” Explained

What Is Retatrutide?

Retatrutide, previously identified by the research code LY3437943, is a once-weekly injectable medication being developed by Eli Lilly.

It is described as a triple hormone receptor agonist because one molecule activates three different receptors:

• Glucose-dependent insulinotropic polypeptide, or GIP
• Glucagon-like peptide-1, or GLP-1
• Glucagon

Each receptor affects metabolism differently.

GLP-1 activity can reduce hunger, increase feelings of fullness, support insulin secretion when glucose is elevated, and slow the movement of food through the stomach.

GIP also helps regulate insulin release and appears to complement the effects of GLP-1 on appetite and nutrient metabolism.

Glucagon has a different role. It can increase liver glucose production, but glucagon-receptor activation may also increase energy expenditure, promote fat oxidation, and influence how the liver processes stored fat.

Retatrutide is designed to balance these three signals within a single molecule. The goal is to reduce appetite and improve glucose control while potentially increasing the amount of energy the body uses.

Some media outlets and online communities refer to retatrutide as a “GLP-3.” Eli Lilly has clarified that this is not a scientifically accurate term. There is no recognized GLP-3 drug class. Retatrutide is more accurately described as a GIP, GLP-1, and glucagon triple agonist.

What Phase of Clinical Trials Is Retatrutide In?

Retatrutide is currently in Phase 3 clinical development.

Eli Lilly has disclosed positive Phase 3 results from five trials:

• TRIUMPH-1
• TRIUMPH-2
• TRIUMPH-3
• TRIUMPH-4
• TRANSCEND-T2D-1

The studies include adults with obesity, overweight, type 2 diabetes, knee osteoarthritis, obstructive sleep apnea, cardiovascular disease, and other weight-related complications.

Additional trials are studying retatrutide for chronic lower-back pain, chronic kidney disease, cardiovascular outcomes, metabolic liver disease, and long-term weight maintenance.

Lilly announced in July 2026 that it plans to submit a Biologics License Application for retatrutide to the FDA during the first quarter of 2027.

That timeline does not guarantee approval. The FDA must review the complete clinical, safety, manufacturing, and quality-control data before retatrutide can be legally marketed.

What Retatrutide Doses Are Being Tested?

Retatrutide does not currently have an FDA-approved dose. Every dose discussed in this article comes from a controlled clinical trial and should not be treated as a prescribing or self-administration protocol.

Phase 2 doses

The Phase 2 obesity trial evaluated weekly target doses of:

• 1 mg
• 4 mg
• 8 mg
• 12 mg

Some participants assigned to higher doses began treatment at 2 mg or 4 mg before gradually increasing to their target dose.

The results helped Lilly select the doses and escalation schedules used in its larger Phase 3 program.

Phase 3 doses

The principal weekly maintenance doses evaluated in the Phase 3 obesity trials are:

• 4 mg
• 9 mg
• 12 mg

Participants generally began with 2 mg once weekly. Their doses were then increased every four weeks until they reached their assigned target.

The studied escalation schedules included:

Target dose of 4 mg:

2 mg → 4 mg

Target dose of 9 mg:

2 mg → 4 mg → 6 mg → 9 mg

Target dose of 12 mg:

2 mg → 4 mg → 6 mg → 9 mg → 12 mg

Some Phase 3 studies involving severe obesity or cardiovascular disease tested only the 9 mg and 12 mg maintenance doses.

Lilly is also conducting a separate Phase 3b trial to investigate whether alternative dose-escalation schedules can improve tolerability.

These schedules were created for monitored clinical trials. They are not instructions for using products sold online as retatrutide.

How Much Weight Loss Has Retatrutide Produced?

The strongest results reported so far have come from the TRIUMPH-1 Phase 3 obesity trial.

TRIUMPH-1 results

TRIUMPH-1 included adults with obesity or overweight and at least one weight-related health condition. Participants with diabetes were excluded from the primary study population.

At 80 weeks, average weight loss was:

Participants receiving 12 mg lost an average of approximately 70 pounds.

About 45% of participants in the 12 mg group lost at least 30% of their starting body weight.

These results came from an efficacy analysis estimating outcomes if participants had remained on treatment without beginning prohibited weight-management treatments. Real-world results may be different because patients may miss doses, discontinue treatment, experience side effects, or respond differently.

TRIUMPH-2 results

TRIUMPH-2 evaluated people with obesity or overweight and type 2 diabetes.

At 80 weeks, participants experienced the following average weight reductions:

Participants receiving retatrutide also experienced average A1C reductions of approximately 1.4 to 1.6 percentage points.

As seen with several other weight-management medications, participants with type 2 diabetes generally lost less weight than participants without diabetes.

TRIUMPH-3 results

TRIUMPH-3 included adults with severe obesity and established cardiovascular disease. Participants could enter the study with or without type 2 diabetes.

At 80 weeks:

Participants receiving the highest dose lost an average of approximately 56 pounds.

The trial also reported improvements in waist circumference, triglycerides, non-HDL cholesterol, systolic blood pressure, and high-sensitivity C-reactive protein.

However, this study was not large enough to establish whether retatrutide prevents heart attacks, strokes, or cardiovascular death. The confidence intervals surrounding the cardiovascular event results were wide, meaning no firm cardiovascular-protection conclusion can currently be made.

Retatrutide Versus Semaglutide

Semaglutide is the active ingredient in medications including Ozempic and Wegovy.

The central difference is the number of receptors each medication activates.

In the STEP 1 clinical trial, adults without diabetes receiving 2.4 mg of semaglutide lost an average of 14.9% of their starting body weight after 68 weeks. Participants receiving placebo lost an average of 2.4%.

In TRIUMPH-1, the 12 mg retatrutide group lost an average of 28.3% after 80 weeks.

These numbers cannot be treated as a direct head-to-head comparison. The studies included different participants, treatment durations, protocols, lifestyle interventions, discontinuation rates, and statistical methods.

Retatrutide has not yet completed a published clinical trial directly comparing it with semaglutide for obesity. Until such data are available, it is not possible to say precisely how much more effective retatrutide would be for the same person under the same conditions.

Semaglutide also has a longer history of regulatory review and real-world use. Its prescribing information, contraindications, drug interactions, pregnancy recommendations, and rare adverse-event risks are better established.

Retatrutide does not yet have an approved prescribing label.

Retatrutide Versus Tirzepatide

Tirzepatide is the active ingredient in Mounjaro and Zepbound.

Tirzepatide activates two receptors:

• GIP
• GLP-1

Retatrutide activates those two receptors and adds glucagon-receptor activity.

In the SURMOUNT-1 obesity trial, participants receiving the highest studied tirzepatide dose lost an average of 20.9% of their body weight after 72 weeks.

Retatrutide produced higher average reductions in its Phase 3 obesity trial, but these were again separate studies.

Lilly is conducting a randomized Phase 3 trial called TRIUMPH-5 that directly compares retatrutide with tirzepatide in adults with obesity. Until that trial is completed, claims that retatrutide is definitively superior to tirzepatide remain premature.

Is Retatrutide Just Another GLP-1?

Retatrutide includes GLP-1 receptor activity, but it is not a GLP-1-only medication.

The term “GLP-1” is often used broadly to describe several different weight-management medications. However, the drugs within this category do not all work in the same way.

Semaglutide is a GLP-1 receptor agonist.

Tirzepatide is a GIP and GLP-1 dual agonist.

Retatrutide is a GIP, GLP-1, and glucagon triple agonist.

The additional glucagon activity is the most distinctive part of retatrutide’s design.

GLP-1 medications primarily promote weight loss by reducing appetite and calorie intake. Retatrutide appears to reduce food intake while potentially influencing energy expenditure and fat metabolism through glucagon-receptor activation.

Researchers are still determining how much of retatrutide’s weight-loss effect comes from reduced appetite and how much comes from changes in energy use.

What Side Effects Have Been Reported?

The most common adverse effects reported in retatrutide trials involve the gastrointestinal system.

These include:

• Nausea
• Diarrhea
• Constipation
• Vomiting
• Reduced appetite
• Abdominal discomfort

The symptoms have generally been most noticeable during dose escalation.

In TRIUMPH-2, nausea occurred in approximately 14% of participants receiving 4 mg, 21% receiving 9 mg, and 28% receiving 12 mg. Diarrhea occurred in approximately 27% to 34% of participants receiving retatrutide.

Treatment discontinuations caused by adverse events varied by dose and study. In TRIUMPH-3, discontinuation rates were 9.8% with 9 mg and 13.5% with 12 mg, compared with 4.8% for placebo.

Dysesthesia

One side effect receiving particular attention is dysesthesia.

Dysesthesia refers to unusual or uncomfortable sensations involving the skin or nerves. It may feel like tingling, burning, numbness, heightened sensitivity, or pain from light touch.

In TRIUMPH-2, dysesthesia occurred in:

• 4.5% of the 4 mg group
• 5.6% of the 9 mg group
• 7.3% of the 12 mg group
• 0.7% of the placebo group

Lilly reported that most cases were mild to moderate and that many resolved during continued treatment.

The final safety profile remains incomplete. Rare adverse effects may not become clear until larger populations use a medication for longer periods.

What Other Conditions Is Retatrutide Being Studied For?

Retatrutide is being investigated for more than weight loss alone.

Current and completed studies include people with:

• Type 2 diabetes
• Knee osteoarthritis
• Obstructive sleep apnea
• Established cardiovascular disease
• Chronic kidney disease
• Chronic lower-back pain
• Metabolic dysfunction-associated steatotic liver disease
• Obesity requiring long-term weight maintenance

Some of the improvements in these conditions may result from weight loss. Others may involve direct metabolic, inflammatory, cardiovascular, or liver-related effects.

Separate trials are needed to determine whether retatrutide should receive approval for each condition.

Can You Buy Retatrutide Now?

Retatrutide is not currently approved for public prescribing or commercial sale.

Eli Lilly states that legitimate retatrutide is available only to participants enrolled in authorized Lilly clinical trials.

Products advertised online as “research retatrutide,” compounded retatrutide, or laboratory-grade retatrutide are not FDA-approved Lilly products.

There is no reliable way for consumers to confirm that these products contain the correct molecule, concentration, dose, or sterile ingredients. They may contain too much active ingredient, too little, the wrong ingredient, or harmful contaminants.

Because retatrutide has no approved dose or prescribing label, a product being sold online should not be interpreted as an early version of an approved medication.

Will Retatrutide Replace Semaglutide or Tirzepatide?

Retatrutide could become an important new obesity treatment, but it is too early to say whether it will replace existing medications.

The strongest dose produced greater average weight loss than semaglutide or tirzepatide produced in their separate pivotal obesity trials. That does not automatically make retatrutide the best medication for every patient.

Treatment decisions also depend on:

• Side effects
• Treatment discontinuation
• Blood-sugar response
• Existing medical conditions
• Cardiovascular outcomes
• Muscle-mass preservation
• Long-term weight maintenance
• Cost
• Insurance coverage
• Medication availability
• Patient preference

A medication producing slightly less weight loss may still be the better choice if it is easier to tolerate, safer for a particular patient, more affordable, or more accessible.

On a GLP-1-based medication? Get our free nutrition guide here to learn how to prevent muscle loss and manage side effects.